Sclerotherapy With Picibanil (OK‐432) for Congenital Lymphatic Malformation in the Head and Neck

Sung, Myung‐Whun; Lee, Dong‐Wook; Kim, Dong Young; Lee, Sang Jun; Hwang, Chan Ho; Park, Seokwoo; Kim, Kwang Hyun

doi:10.1097/00005537-200108000-00020

Cited by 87 publications

(75 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous reports have stated that surgical 86 Motz et al, OK432 Versus Doxycycline for Lymphatic Malformations excision is not more complicated after OK432 sclerotherapy. 2,3,[22][23][24]27,28 We found this to be true in the excision of an organized hematoma.…”

mentioning

confidence: 68%

OK432 Versus Doxycycline for Treatment of Macrocystic Lymphatic Malformations

Motz

Nickley

Bedwell

et al. 2014

Ann Otol Rhinol Laryngol

View full text Add to dashboard Cite

Objectives: A variety of sclerotherapy agents are used to treat macrocystic lymphatic malformations (LMs). This retrospective study at a single institution was performed to compare the outcomes of pediatric macrocystic LMs of the head and neck that were treated with doxycycline or with OK432. Methods:The outcomes measured included early response to therapy, number of treatments required, operating room time, and adverse events. Results:The rates of clinical success for OK432 and doxycycline were similar (83% and 82%, respectively; p > 0.05), although OK432-treated patients required more treatments than did doxycycline-treated patients (1.9 versus 1.0 injections; p = 0.01; 95% confidence interval, 1.57 to 0.27). The average operating room time for a single OK432 injection was significantly shorter than that for doxycycline (53.2 versus 98.1 minutes; p < 0.001); however, when the total number of treatments administered was considered, the overall times in the operating room were similar. Adverse events in the early postoperative period were more common in OK432-treated patients, who experienced marked postoperative swelling compared to doxycycline-treated patients.Conclusions: OK432 and doxycycline are both effective sclerosants for the treatment of predominantly macrocystic LMs. The administration time for OK432 is shorter than that for doxycycline, but OK432 required more treatments overall to achieve clinical success. Early adverse events were more common in OK432-treated patients, but longer follow-up is necessary to determine whether rates of recurrence and adverse events are similar, particularly in light of the risk of tooth discoloration in doxycycline-treated patients.

show abstract

mentioning

confidence: 68%

OK432 Versus Doxycycline for Treatment of Macrocystic Lymphatic Malformations

Motz

Nickley

Bedwell

et al. 2014

Ann Otol Rhinol Laryngol

View full text Add to dashboard Cite

show abstract

“…104 Sclerotherapy is typically ineffective in treating microcystic LMs, although positive treatment outcomes have been reported with doxycycline, 105 bleomycin 91 and OK-432. 106 In addition, an intermediate response in 50% of cases has also been observed. 94 Thus, sclerotherapy may provide benefit to patients with symptomatic and/or large microcystic LMs.…”

Section: Lymphatic Malformationsmentioning

confidence: 98%

Vascular anomalies: classification, imaging characteristics and implications for interventional radiology treatment approaches

Mulligan

Prajapati²,

Martin

et al. 2014

BJR

169

132

View full text Add to dashboard Cite

The term vascular anomaly represents a broad spectrum of vascular pathology, including proliferating vascular tumours and vascular malformations. While the treatment of most vascular anomalies is multifactorial, interventional radiology procedures, including embolic therapy, sclerotherapy and laser coagulation among others, are playing an increasingly important role in vascular anomaly management. This review discusses the diagnosis and treatment of common vascular malformations, with emphasis on the technique, efficacy and complications of different interventional radiology procedures.

show abstract

“…The regimen is an effective treatment for unresectable lesions, incomplete resection and recurrent lymphatic malformations (Ogita et al 1991(Ogita et al , 1994Mikhail et al 1995). Some authors considered sclerotherapy with OK-432 to be the initial treatment for lymphatic malformations (Ogita et al 1994;Luzzatto et al 2000;Sung et al 2001). 92%-100% of patients with macrocystic lesions and 41-60% of patients with microcystic lesions have a favorable response (Ogita et al 1994;Luzzatto et al 2000;Sanlialp et al 2003).…”

Section: Discussionmentioning

confidence: 99%

“…Ogita et al (1987Ogita et al ( , 1991Ogita et al ( , 1994 also suggested that the local inflammation caused by OK-432 did not cause any damage to the overlying skin and did not lead to scar formation. However, transient facial nerve palsy after sclerotherapy with OK-432 at the parotid area has previously been reported, and believed that stretching of the nerve by swelling was regarded as the principal cause (Sung et al 2001).…”

Section: Discussionmentioning

confidence: 99%

“…To prevent the adverse effects caused by extravasation of the sclerosing agent or unintentional vascular injection (Berenguer et al 1999;Sung et al 2001;Puig et al 2003), Ogita et al (1987) suggested the volume of sclerosing agent injected should be the same as fluid aspirated for macrocystic lesions, while double-needle methods and placement of a pigtail catheter were used to minimize extravasation (Dubois et al 1997;Puig et al 2003;Won et al 2004). Sonography, computed tomography and magnetic resonance image were also reported to guide the procedure (Molitch et al 1995;Lewin et al 1999;Luzzatto et al 2000).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Facial Nerve Conduction after Sclerotherapy in Children with Facial Lymphatic Malformations: Report of Two Cases

Lin

Guo

Lin

et al. 2007

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Surgical excision is thought to be the standard treatment of choice for lymphatic malformations. However, when the lesions are limited to the face only, surgical scar and facial nerve injury may impair cosmetics and facial expression. Sclerotherapy, an injection of a sclerosing agent directly through the skin into a lesion, is an alternative method. By evaluating facial nerve conduction, we observed the long-term effect of facial lymphatic malformations after intralesional injection of OK-432 and correlated the findings with anatomic outcomes. One 12-year-old boy with a lesion over the right-side preauricular area adjacent to the main trunk of facial nerve and the other 5-year-old boy with a lesion in the left-sided cheek involving the buccinator muscle were enrolled. The follow-up data of more than one year, including clinical appearance, computed tomography (CT) scan and facial nerve evaluation were collected. The facial nerve conduction study was normal in both cases. Blink reflex in both children revealed normal results as well. Complete resolution was noted on outward appearance and CT scan. The neurophysiologic data were compatible with good anatomic and functional outcomes. Our report suggests that the inflammatory reaction of OK-432 did not interfere with adjacent facial nerve conduction.

show abstract

Sclerotherapy With Picibanil (OK‐432) for Congenital Lymphatic Malformation in the Head and Neck

Cited by 87 publications

References 8 publications

OK432 Versus Doxycycline for Treatment of Macrocystic Lymphatic Malformations

OK432 Versus Doxycycline for Treatment of Macrocystic Lymphatic Malformations

Vascular anomalies: classification, imaging characteristics and implications for interventional radiology treatment approaches

Facial Nerve Conduction after Sclerotherapy in Children with Facial Lymphatic Malformations: Report of Two Cases

Contact Info

Product

Resources

About